ClinicalTrials.gg
CompletedNCT02339246ASTCOFFUpdated Jan 18, 2016Results posted

Pharmacokinetic Comparison Of All FK-506 Formulations

A Phase 3 interventional study of Prograf vs Envarsus XR vs Astagraf XL and Prograf vs Astagraf XL vs Envarsus XR in Renal Failure, sponsored by Veloxis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-18.

Sponsored by Veloxis Pharmaceuticals · Phase 3, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing tacrolimus in Renal Insufficiency — none open to participants now, 1 under way, 1 of them phase 3. Tacrolimus · Renal Insufficiency.

Enrollment
15th of 17
32 · median 50
Started
2015
the only one that year
Phase 3
6 of 17
none open now
Registered
15th of 17
by date
Lead sponsor
8 of 17
Veloxis Pharmaceuticals

Among the 17 studies testing tacrolimus in Renal Insufficiency, this one is the 15th largest by enrollment, is the only one that started in 2015, is one of 6 in phase 3, and was the 15th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 17 studies testing tacrolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing tacrolimus in Renal Insufficiency as a file.
02

Study summary

The purpose of the study is to compare the pharmacokinetic parameters of three different formulations of tacrolimus.

Eligible patients will be treated with all three formulations in a pre-defined sequence.

Read the detailed description

The pharmacokinetic parameters T(max), C(max) and AUC(0-24) will be compared between the three formulations Envarsus XR once daily, Astagraf XL once daily and Prograf Twice daily.

03

Conditions studied

  • Renal Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Renal transplant recipients, males or females, of 18 years of age or above.
  2. Able to participate and willing to give written and to comply with study visits and restrictions.
  3. Able to understand English.
  4. Patients having received a primary or secondary renal transplant

Exclusion criteria

Exclusion Criteria:

  1. Evidence of acute rejection episode within the past three months prior to screening.
  2. Recipients of organ transplants other than kidney.
  3. Patients who are known to be positive.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Prograf vs Envarsus XR vs Astagraf XL

    Prograft capsules Twice daily for 7 days, followed by Envarsus XR tablets once daily for 7 days followed by Astagraf XL capsules once daily for 7 days.

    Drug: Prograf vs Envarsus XR vs Astagraf XL

  • Active comparator
    Prograf vs Astagraf XL vs Envarsus XR

    Prograf capsules twice daily for 7 days followed by Astagraf XL capsules once daily for 7 days followed by Envarsus XR tablets once daily.

    Drug: Prograf vs Astagraf XL vs Envarsus XR

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of T(Max) for Envarsus XR, Astagraf XL and Prograf.

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate T(max). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.

    Time frame: 8 days

  2. Evaluation of C(Max) for Envarsus XR, Astagraf XL and Prograf.

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate C(max). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.

    Time frame: 8 days

  3. Evaluation of AUC(0-24) for Envarsus XR, Astagraf XL and Prograf.

    Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate AUC(0-24). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.

    Time frame: 8 days

07

Results

Posted Jan 18, 2016

Participant flow

32 patients were screened (enrolled) and 31 were randomized to treatment.

First Intervention (7 Days)
Participant flow — First Intervention (7 Days)
MilestoneEnvarsus XRAstagraf XLPrograf
Started0031
Completed0031
Not completed000
Second Intervention (7 Days)
Participant flow — Second Intervention (7 Days)
MilestoneEnvarsus XRAstagraf XLPrograf
Started16150
Completed16150
Not completed000
Third Period (7 Days)
Participant flow — Third Period (7 Days)
MilestoneEnvarsus XRAstagraf XLPrograf
Started15160
Completed15160
Not completed000

Outcome measures

PrimaryEvaluation of T(Max) for Envarsus XR, Astagraf XL and Prograf.

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate T(max). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.

Time frame:
8 days
Reported as:
Median · hour
Evaluation of T(Max) for Envarsus XR, Astagraf XL and Prograf.
hourEnvarsus XRAstagraf XLPrograf
Evaluation of T(Max) for Envarsus XR, Astagraf XL and Prograf.5.91 (1.45 to 13.95)1.93 (0.92 to 5.92)1.48 (0.93 to 19.97)
PrimaryEvaluation of C(Max) for Envarsus XR, Astagraf XL and Prograf.

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate C(max). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.

Time frame:
8 days
Reported as:
Mean · ng/mL
Evaluation of C(Max) for Envarsus XR, Astagraf XL and Prograf.
ng/mLEnvarsus XRAstagraf XLPrograf
Evaluation of C(Max) for Envarsus XR, Astagraf XL and Prograf.13.88 ± 5.33113.17 ± 12.4914.54 ± 13.60
PrimaryEvaluation of AUC(0-24) for Envarsus XR, Astagraf XL and Prograf.

Tacrolimus whole blood concentrations obtained from the central lab was used for PK analysis. Actual sampling times was used to calculate AUC(0-24). Nominal time points used were: Prograf sampling strategy (21 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, and 24. Envarsus XR sampling strategy (18 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, 24, and 27. Astagraf XL sampling strategy (17 samples): Pre-dose (C0) and then 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 14, 16, 18, 21, and 24.

Time frame:
8 days
Reported as:
Mean · hr*ng/mL
Evaluation of AUC(0-24) for Envarsus XR, Astagraf XL and Prograf.
hr*ng/mLEnvarsus XRAstagraf XLPrograf
Evaluation of AUC(0-24) for Envarsus XR, Astagraf XL and Prograf.213.41 ± 83.095165.02 ± 48.910176.52 ± 50.799

Adverse events

Collected over Adverse events were collected from time of first dose of study drug and until last visit which was approximately 1 month.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Envarsus XR—0/31 (0%)2/31 (6.5%)
Astagraf XR—0/31 (0%)10/31 (32.3%)
Prograf—0/31 (0%)3/31 (9.7%)
Most frequent other events
Most frequent other events
EventEnvarsus XRAstagraf XRPrograf
Oedema peripheralGeneral disorders0/313/310/31
DiarrheaGastrointestinal disorders0/312/311/31
VomitingGastrointestinal disorders0/312/310/31
FatigueGeneral disorders2/310/310/31
NasopharyngitisInfections and infestations0/312/310/31
HeadacheNervous system disorders0/311/312/31

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Prograf vs Envarsus XR vs Astagraf XLPrograf vs Astagraf XL vs Envarsus XRTotal
<=18 years000
Between 18 and 65 years151429
>=65 years112
Age, Continuous
Age, Continuous(years)Prograf vs Envarsus XR vs Astagraf XLPrograf vs Astagraf XL vs Envarsus XRTotal
Mean50.1 ± 11.0046.3 ± 13.3048.3 ± 12.11
Sex: Female, Male
Sex: Female, Male(Participants)Prograf vs Envarsus XR vs Astagraf XLPrograf vs Astagraf XL vs Envarsus XRTotal
Female7613
Male9918
Region of Enrollment
Region of Enrollment(participants)Prograf vs Envarsus XR vs Astagraf XLPrograf vs Astagraf XL vs Envarsus XRTotal
United States161531
08

Study locations

1 site
  • University of Cincinnati
    Cincinnati, Ohio 45267-2827, United States
09

References and documents

Publications

  • Philosophe B, Leca N, West-Thielke PM, Horwedel T, Culkin-Gemmell C, Kistler K, Stevens DR. Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended-Release Once-Daily Tacrolimus Tablets. J Clin Pharmacol. 2018 Jul;58(7):891-896. doi: 10.1002/jcph.1082. Epub 2018 Feb 20. PubMed 29462506 ↗
  • Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. Am J Transplant. 2017 Feb;17(2):432-442. doi: 10.1111/ajt.13935. Epub 2016 Aug 2. PubMed 27340950 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2014
First posted
Jan 15, 2015
Start
Jan 2015
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Jan 18, 2016
Last update
Jan 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02339246
Lead sponsor
Veloxis Pharmaceuticals
Responsible party
Sponsor
First posted
Jan 15, 2015
Start date
Jan 2015
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Jan 18, 2016
Last update
Jan 18, 2016

Study contacts

Rita Alloway, PharmD
principal investigator · University of Cincinnati

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion